🔬 We successfully organized and conducted the iDMC for Phase I, Randomized, Double Blind, Placebo-Controlled, Safety, Reactogenicity, and Immunogenicity Trial of the SARS-CoV-2 Vaccine in Healthy Volunteers. This milestone marks a significant step forward in the fight against COVID-19.
📃 We have officially finalized the CSR for the randomized double-blinded multi-center study in patients with primary osteoarthritis grade 3-4 according to the Kellgren-Lawrence classification by our Medical Writing and Biostatistics team. This comprehensive report represents the culmination of extensive research and analysis, providing valuable insights into osteoarthritis treatment.
💻 Our team has completed the development of SDTM and Adam datasets in the Medical Device study. This achievement showcases our commitment to delivering high-quality data and ensuring accurate analysis in medical device research.
🔍 We are proud to announce the successful completion of the Psoriatic Arthritis Phase III study project. This marks an important milestone in advancing our understanding and treatment of psoriatic arthritis, benefiting patients and healthcare professionals alike.
This is an important milestone for our team for sure! Our dedicated team has worked tirelessly to ensure that this study is conducted with the highest standards of quality, participation in the study gave us a great experience, thanks to the Sponsor for the opportunity to participate in the project.
We are deeply grateful to all team members, who have contributed to the success of this project to date, we also appreciate the continued support of our partners, who have helped make this study possible. Your cooperation and commitment has helped move things forward!